Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Sangeetha Venugopal, Sanam Loghavi, Mark Routbort, Fatima Zahra Jelloul, Rashmi Kanagal-Shamanna, Sherry A. Pierce, Ghayas C. Issa, Hussein A Abbas, Koji Sasaki, Koichi Takahashi, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 6328–6330.

https://doi.org/10.1182/blood-2022-169778

Published: 2022

Journal Articles

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

Sangeetha Venugopal, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Abhishek Maiti, Musa Yilmaz, Ghayas C. Issa, Kelly S. Chien, Sherry A. Pierce, Hagop Kantarjian, Nicholas J. Short

Blood (2021) 138 (Supplement 1): 794.

https://doi.org/10.1182/blood-2021-153960

Published: 2021

Journal Articles

Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials

Sangeetha Venugopal, Elias J. Jabbour, Naveen Pemmaraju, Guillermo Montalban-Bravo, Kelly S. Chien, Naval Daver, Nitin Jain, Jan A. Burger, Yesid Alvarado, Abhishek Maiti, Courtney D. DiNardo, Gautam Borthakur, Rashmi Malla, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia

Blood (2021) 138 (Supplement 1): 4420.

https://doi.org/10.1182/blood-2021-153044

Published: 2021

Journal Articles

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Sangeetha Venugopal, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Koji Sasaki, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2021-153475

Published: 2021

Journal Articles

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Sangeetha Venugopal, Nicholas J. Short, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Sherry A. Pierce, Sanam Loghavi, Keyur P. Patel, Ghayas C. Issa, Hagop Kantarjian, Sa A Wang, Farhad Ravandi

Blood (2021) 138 (Supplement 1): 2374.

https://doi.org/10.1182/blood-2021-154105

Published: 2021

Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Sangeetha Venugopal, Hagop Kantarjian, Nicholas J. Short, Philip A. Thompson, Naveen Pemmaraju, Nitin Jain, William G. Wierda, Gautam Borthakur, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Jennifer Thankachan, Benjamin Nwakanme, Rebecca Garris, Elias J. Jabbour

Blood (2021) 138 (Supplement 1): 1239.

https://doi.org/10.1182/blood-2021-153826

Published: 2021

Journal Articles

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Sai Prasad Prasad Desikan, Guillermo Montalban-Bravo, Maro Ohanian, Naval Daver, Musa Yilmaz, Marina Konopleva, Tapan M. Kadia, Sangeetha Venugopal, Heather Schneider, Kelly S. Chien, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2021-153170

Published: 2021

Journal Articles

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2021-154059

Published: 2021

Journal Articles

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Sangeetha Venugopal, Hagop Kantarjian, Abhishek Maiti, Nicholas J. Short, Guillermo Montalban-Bravo, Yesid Alvarado, Kelly S. Chien, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Elias J. Jabbour, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 245.

https://doi.org/10.1182/blood-2021-153657

Published: 2021

Journal Articles

Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms

Sangeetha Venugopal, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Lucia Masarova, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-143131

Published: 2020

Journal Articles

Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study

Douglas Tremblay, Maaike van Gerwen, Mathilda Alsen, Santiago Thibaud, Alaina Kessler, Sangeetha Venugopal, Iman Makki, Qian Qin, Sirish Dharmapuri, Tomi Jun, Sheena Bhalla, Shana Berwick, Jonathan Feld, John Mascarenhas, Kevin Troy, Caroline Cromwell, Andrew Dunn, William K. Oh, Leonard Naymagon

Blood (2020) 136 (1): 144–147.

https://doi.org/10.1182/blood.2020006941

Published: 2020

Includes: Supplemental data

Journal Articles

Refractory gout in primary myelofibrosis

Sangeetha Venugopal, John Mascarenhas

Blood (2019) 133 (23): 2550.

https://doi.org/10.1182/blood.2019000537

Published: 2019

Journal Articles

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Anne S. Renteria, MD, Sangeetha Venugopal, MD, Bridget Marcellino, MD PhD, Alla Keyzner, MD, Marina Kremyanskaya, MD PhD, Vesna Najfeld, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2018-99-115634

Published: 2018

NARROW

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms

Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study

Refractory gout in primary myelofibrosis

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only